{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:47:57Z","timestamp":1793468877732,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006703","name":"Universit\u00e9 de Bretagne Occidentale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nucl. Med."],"abstract":"<jats:p>Currently, prognostic models in diffuse large B-cell lymphoma (DLBCL) fail to closely reflect patients' biological, clinical, and survival heterogeneity. We, therefore, assessed the impact of clinical, biological, immunohistochemical (IHC), baseline (0), and interim (after 2 and 4 treatment cycles) PET (PET0, PET2, and PET4) data not yet included in any scoring system on DLBCL outcome. The analysis was conducted on 89 previously untreated adult patients of the Finistere Observatory Cohort (O.Ly.Fin) with documented DLBCL, recruited between January 2010 and December 2017, with progression-free survival (PFS) and overall survival (OS) as primary and secondary endpoints, respectively. Seventy-eight patients were treated with rituximab, cyclophosphamide, hydroxyadriamycin, vincristine, and prednisone (R-CHOP), while 11 received R-dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and hydroxyadriamycin (EPOCH). Patients were followed up until June 20, 2020. On multivariate analysis, Ki67 \u2265 70% on IHC (K), bulky presentation \u22657.5 cm (B), meningeal lymphomatosis (M), and PET0\u2013PET4 \u0394SUVmax &amp;lt;71% (P4) were identified as strong independent predictors of PFS, and all variables but bulky disease also strongly and independently predicted OS. Using these 4 parameters, we designed a scoring model named KBMP4 stratifying patients into low- (0 parameter), intermediate- (1 or 2), and high-risk (\u22653) subgroups by the Kaplan\u2013Meier analysis. At a median follow-up of 43 months, PFS and OS were both 100% in the low-risk subgroup, 71.4 and 90.5%, respectively, in the intermediate-risk subgroup, and 0 and 55.5%, respectively, in the high-risk subgroup. Use of the KBMP4 model in clinical practice may improve accuracy in prognostic prediction and treatment decisions in <jats:italic>de novo<\/jats:italic> DLBCL patients.<\/jats:p>","DOI":"10.3389\/fnume.2022.829138","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T04:48:43Z","timestamp":1649306923000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Ki67 Immunohistochemical Expression Level \u226570%, Bulky Presentation \u22657.5 cm, Meningeal Lymphomatosis, and Interim PET \u0394SUVmax After 4 Treatment Cycles &lt;71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma"],"prefix":"10.3389","volume":"2","author":[{"given":"Vincent","family":"Rebi\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Maajem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Le Calloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leela","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Le Bris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Malou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Quintin-Rou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Tempescul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Samaison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Salaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Berthou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Abgral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Richard","family":"Eveillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"B1","volume-title":"Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition","author":"Swerdlow","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S1470-2045(15)00005-4","article-title":"Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas","volume":"16","author":"Sarkozy","year":"2015","journal-title":"Lancet Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1002\/cncr.30895","article-title":"C-MYC-positive relapsed and refractory diffuse large B-cell lymphoma: impact of additional \u201chits\u201d and outcomes with subsequent therapy","volume":"123","author":"Epperla","year":"2017","journal-title":"Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjh.12763","article-title":"MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"165","author":"Perry","year":"2014","journal-title":"Br J Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature."},{"key":"B10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B-cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis","volume":"14","author":"Guo","year":"2019","journal-title":"PLoS ONE."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","article-title":"Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis","volume":"48","author":"Lin","year":"2007","journal-title":"J Nucl Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"109301","DOI":"10.1016\/j.ejrad.2020.109301","article-title":"Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET\/CT","volume":"133","author":"Li","year":"2020","journal-title":"Eur J Radiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hon.2805","article-title":"Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38\/07 clinical trial","volume":"38","author":"Zucca","year":"2020","journal-title":"Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure \u2013 what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology Am Soc Hematol Educational Program"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisopne, vincristin, cyclophosphamide, doxorubicine and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, munticentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol."},{"key":"B22","author":"Magnusson","year":"2021","journal-title":"No difference in overall survival between R-CHOP and R-EPOCH among patients with advanced stage MYC-rearranged, double hit or triple hit diffuse large B-cell lymphoma."},{"key":"B23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2020008750","article-title":"Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1080\/10428194042000198849","article-title":"Distribution and prognosis of WHO Lymphoma Subtypes in Taiwan Reveals a Low incidence of germinal-center derived tumors","volume":"45","author":"Chang","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4149\/neo_2013_010","article-title":"The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"60","author":"Benesova","year":"2013","journal-title":"Neoplasma"},{"key":"B34","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1600-0609.2012.01778.x","article-title":"High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy","volume":"88","author":"Li","year":"2012","journal-title":"Eur J Haematol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7574","article-title":"Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL\/GLA","author":"Pfreundschuh","year":"2018","journal-title":"J Clin Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","article-title":"Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"10175","DOI":"10.2147\/CMAR.S225372","article-title":"Central nervous system involvement in patients with diffuse large B-cell lymphoma: analysis of the risk factors and prognosis from a single-center retrospective cohort study","volume":"11","author":"Ma","year":"2019","journal-title":"Cancer Manag Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"Abramson","year":"2010","journal-title":"Cancer."},{"key":"B39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.critrevonc.2016.07.003","article-title":"Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis","volume":"106","author":"Adams","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1080\/10428194.2018.1562181","article-title":"PET-derived tumor metrics predict DLBCL response and progression free survival","volume":"60","author":"Islam","year":"2018","journal-title":"Leukemia Lymphoma"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.18632\/oncotarget.27103","article-title":"Predictive value of interim FDG-PET\/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"10","author":"Kitajima","year":"2019","journal-title":"Oncotarget."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e2808","DOI":"10.1097\/MD.0000000000002808","article-title":"Predictive significance of a new prognostic score for patients with diffuse large B-cell lymphoma in the interim-positron emission tomography findings","volume":"95","author":"Kong","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1200\/JCO.2017.74.7360","article-title":"Succeeding in breaking the R-CHOP ceiling in DLBCL: learning from negative trials","volume":"35","author":"Goy","year":"2017","journal-title":"J Clin Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Nuclear Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2022.829138\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T04:48:47Z","timestamp":1649306927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2022.829138\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":48,"alternative-id":["10.3389\/fnume.2022.829138"],"URL":"https:\/\/doi.org\/10.3389\/fnume.2022.829138","relation":{},"ISSN":["2673-8880"],"issn-type":[{"value":"2673-8880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"article-number":"829138"}}